Osteoarthritis Knee Pain
4
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
4
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Prevail TherapeuticsNY - New York
4 programs4
DuloxetinePhase 3
DuloxetinePhase 3
DuloxetinePhase 3
DuloxetinePhase 3
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Saol TherapeuticsSL1002
Eli Lilly and CompanyDuloxetine
Clinical Trials (2)
Total enrollment: 674 patients across 2 trials
Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain
Start: Nov 2025Est. completion: Feb 2027150 patients
Phase 3Recruiting
A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis
Start: Nov 2009Est. completion: Apr 2011524 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 674 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.